Login / Signup

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.

Marco GalluzzoMarina TalamontiClara De SimoneSimone D'AdamioGaia MorettaSara TamboneGiacomo CaldarolaMaria Concetta FargnoliKetty PerisLuca Bianchi
Published in: Expert opinion on biological therapy (2018)
Secukinumab was effective in this real-life analysis, with rapid clinical improvement and long-term maintenance of results.
Keyphrases
  • ankylosing spondylitis
  • coronary artery disease
  • high intensity
  • early onset
  • cross sectional
  • quantum dots
  • drug induced
  • sensitive detection